Cite
HARVARD Citation
Crassini, K. et al. (2018). MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT‐737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment. British journal of haematology. pp. 360-372. [Online].